Lupin Marks Its Second Canadian Biosimilar Approval With Pegfilgrastim
US FDA Decision For The Pegfilgrastim Biosimilar Is Expected Later In The Fiscal Year
With several other competitors with pegfilgrastim biosimilars already on the Canadian market, Lupin celebrates its second regional approval.
